ProCE Banner Series

Optimizing BTK Inhibitor Therapy in CLL: Updates and Strategies for Oncology Pharmacists

Join us online for this interactive webinar with pharmacy experts discussing the latest recommendations for optimizing BTK inhibitor–based treatment in patients with chronic lymphocytic leukemia (CLL) including monitoring and managing treatment associated toxicities, evaluating drug–drug interactions, and more!

  ACPE-P
Who Should Attend

This program is intended for oncology/hematology pharmacists and other clinical practice stakeholders caring for patients with CLL.

All Events

Optimizing BTK Inhibitor Therapy in CLL: Updates and Strategies for Oncology Pharmacists

Upcoming Events

May

08

2025

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

May

21

2025

7:00 PM - 8:00 PM Eastern Time (ET)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve learners’ knowledge, confidence, and competence in the individualization of BTKi therapy in patients with CLL, including treatment selection and AE management.

Target Audience
This activity is intended for oncology/hematology pharmacists and other clinical practice stakeholders caring for patients with CLL.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Differentiate covalent and noncovalent BTK inhibitors according to selectivity, binding, efficacy and AE profiles
  • Integrate guideline recommendations, current evidence, prognostic information and staging, and patient factors and preferences to the selection of first-line BTK inhibitor therapy for CLL
  • Formulate individualized treatment plans for the selection and sequencing of BTK inhibitor therapy in relapsed/refractory CLL based on factors including intolerance to prior therapy, duration of remission, and presence of resistance mutations
  • Use evidence-based strategies to monitor and manage AEs and address challenges to adherence and access to treatments in CLL

Accreditation

CE Accreditation

Pharmacists

This activity is jointly provided by ProCE, LLC and Clinical Care Options, LLC. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-25-008-L01-P has been assigned to this live application-based activity (initial release date 5/8/2025). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by ProCE, LLC in partnership with Clinical Care Options, LLC.

ProCE, LLC

Supporters

Supported by educational grants from AstraZeneca and Lilly.

AstraZeneca

Lilly

Partners

Clinical Care Options, LLC

ProCE Banner

For customer support please email: customersupport@clinicaloptions.com

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191